Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer

被引:25
|
作者
Liu, Jen-Jane [1 ]
Lichtensztajn, Daphne Y. [2 ]
Gomez, Scarlett Lin [2 ]
Sieh, Weiva [3 ]
Chung, Benjamin I. [1 ]
Cheng, Iona [2 ]
Brooks, James D. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA
[2] Canc Prevent Inst Calif, Fremont, CA USA
[3] Stanford Univ, Sch Med, Div Epidemiol, Dept Hlth Res & Policy, Stanford, CA 94305 USA
关键词
SEER Program; prostatic neoplasms; lymph node metastasis; Gleason score; ACTIVE SURVEILLANCE; REPRODUCIBILITY; ADENOCARCINOMA; CARCINOMA; IMPACT; GRADE;
D O I
10.1097/PAT.0000000000000097
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Based on revisions of Gleason scoring in 2005, it has been reported that nodal metastases at radical prostatectomy in Gleason 3 + 3 = 6 (GS6) prostate cancer are extremely rare, and that GS6 cancers with nodal metastases are invariably upgraded upon review by academic urological pathologists. We analysed the prevalence and determinants of nodal metastases in a national sample of patients with GS6 cancer. We utilised the SEER database to identify patients diagnosed with GS6 prostate cancer during 2004-2010 who had radical prostatectomy and >= 1 lymph node(s) examined. We calculated the prevalence of nodal metastases and constructed a multivariable logistic regression model to identify factors associated with nodal metastases. Among 21,960 patients, the prevalence of nodal metastases was 0.48%. Older age, preoperative PSA >10 ng/mL, and advanced stage were positively associated with nodal metastases. Lymph node metastases in GS6 cancer are more prevalent in a nationwide population compared to academic centres. Revised guidelines for Gleason scoring have made GS6 cancer a more homogeneously indolent disease, which may be relevant in the era of active surveillance. We submit that lymph node metastases in GS6 cancer be used as a proxy for adherence to the 2005 ISUP consensus on Gleason grading.
引用
收藏
页码:306 / 310
页数:5
相关论文
共 50 条
  • [1] Re: Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer
    Kryvenko, Oleksandr N.
    Epstein, Jonathan I.
    PATHOLOGY, 2015, 47 (04) : 394 - 394
  • [2] Clinical Significance of Prospectively Assigned Gleason Tertiary Pattern 4 in Contemporary Gleason Score 3+3=6 Prostate Cancer
    Doshi, Chirag
    Vacchio, Michael
    Attwood, Kristopher
    Murekeyisoni, Christine
    Mehedint, Diana C.
    Badkhshan, Shervin
    Azabdaftari, Gissou
    Sule, Norbert
    Guru, Khurshid A.
    Mohler, James L.
    Kauffman, Eric C.
    PROSTATE, 2016, 76 (08): : 715 - 721
  • [3] Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer
    Ko, Kyungtae
    Jeong, In Gab
    Choi, Woo Suk
    Lim, Ju Hyun
    Suh, Ja Hee
    Ku, Ja Hyeon
    Park, Yangsoon
    Moon, Kyung Cheol
    Kim, Hyeon Hoe
    Kim, Choung-Soo
    Kwak, Cheol
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (09): : 6141 - 6148
  • [4] Is Grade Group 1 (Gleason score 3+3=6) adenocarcinoma of the prostate really cancer?
    Epstein, Jonathan I.
    CURRENT OPINION IN UROLOGY, 2022, 32 (01) : 91 - 95
  • [5] Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?
    Montironi, Rodolfo
    Scarpelli, Marina
    Mazzucchelli, Roberta
    Lopez-Beltran, Antonio
    Santoni, Matteo
    Briganti, Alberto
    Montorsi, Francesco
    Cheng, Liang
    DIAGNOSTIC PATHOLOGY, 2014, 9 : 190
  • [6] Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer
    Kryvenko, Oleksandr N.
    Epstein, Jonathan I.
    PROSTATE, 2016, 76 (12): : 1130 - 1131
  • [7] Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3+3=6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance
    Hassan, Oudai
    Han, Misop
    Zhou, Amy
    Paulk, Adina
    Sun, Yue
    Al-Harbi, Abdullah
    Alrajjal, Ahmed
    dos Santos, Filipa Baptista
    Epstein, Jonathan I.
    JOURNAL OF UROLOGY, 2018, 199 (06): : 1483 - 1487
  • [8] Risk of lymph node metastases in pathological gleason score ≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases
    Wenger, Hannah
    Weiner, Adam B.
    Razmaria, Aria
    Paner, Gladell P.
    Eggener, Scott E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (01) : 31.e1 - 31.e6
  • [9] Gleason score 3+3[6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients
    Samaratunga, Hemamali
    Egevad, Lars
    Yaxley, John
    Perry-Keene, Joanna
    Le Fevre, Ian
    Kench, James
    Matsika, Admire
    Bostwick, David
    Iczkowski, Kenneth
    Delahunt, Brett
    PATHOLOGY, 2024, 56 (01) : 33 - 38
  • [10] Favorable Gleason 3+4 Prostate Cancer Shows Comparable Outcomes With Gleason 3+3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance
    Lee, Hakmin
    Lee, In Jae
    Byun, Seok-Soo
    Lee, Sang Eun
    Hong, Sung Kyu
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E1117 - E1122